A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

January 11, 2018